“…Multiple reports have shown that miR-664a-3p, which is genomically located in the intron of RAB3 GTPase Activating Non-Catalytic Protein Subunit 2 (RAB3GAP2), is abnormally expressed in a number of cancers, including gastric cancer, cervical cancer, osteosarcoma, breast cancer, and T-cell acute lymphoblastic leukaemia [15] , [16] , [17] , [18] , [19] . Another study demonstrated that there were increased levels of miR-664a-3p in EVs in granulomatosis with polyangiitis (GPA), which could be used to discriminate between active GPA and remission [20] . However, it is unclear whether miR-664a-3p expression is altered in pancreatic cancer tissues or plasma sEV.…”